After weeks of speculation, it was officially confirmed on Monday (May 14) Aurora Cannabis (TSX:ACB) will buy competing licensed producer MedReleaf (TSX:LEAF) for a nearly C$3.2 billion transaction.

This time Aurora’s acquisition is set to be done in a friendly manner as it was MedReleaf who originally was rumored to be searching for another player to buy them. Both boards of directors for the companies are in agreement with the transaction, according to an investor presentation sheet on the deal.

The presentation revealed the combined company will hold a funded capacity of over 570,000 kilograms per year. The document also indicated shareholders for both companies will hold special meetings during the month of July in order to approve the transaction.

Shareholders of MedReleaf will get 3.575 common shares of Aurora for each LEAF share held. Once the deal is completed, according to the announcement, existing Aurora and MedReleaf investors will own 61 and 39 percent respectively of the pro forma company on a fully diluted basis.

The terms of the deal represent a price of C$29.44 per MedReleaf common share, with an additional 34 percent premium. MedReleaf’s close on Friday (May 11) was C$24.90.

Any concern for delays on the proposed acquisition is erased since the document says 56 percent of MedReleaf investors “have entered into irrevocable hard lock-ups” with Aurora and vote in support of the arrangement.

Aurora needs at least 66 ⅔ percent–two thirds–of the shareholder vote from MedReleaf during their special meeting in order to complete the transaction.

Thanks to the acquisition, Aurora will enter the Ontario market with the three facilities MedReleaf holds.

Acquisition will expand medical outreach for Aurora internationally

Neil Closner, CEO of MedReleaf, said in a statement by combining with Aurora, the new entity will be “ideally positioned to set the global standard for our industry at a pace that will be difficult to match.”

The presentation also shows the combined company will now hold a debt sheet of C$254 million and a war chest worth approximately C$385 million. The new entity will have a presence in international markets like Australia, Brazil, Germany, Denmark, Sweden and South Africa.

Terry Booth, CEO of Aurora, said the acquisition will strengthen its position to serve the global medical cannabis market, which Closner told INN remains the biggest market option available for companies in the space.

Shareholders of Aurora will now have to face dilution for their shares as the company prepares to acquire the fellow LP. This process comes on the heels off the CanniMed acquisition causing dilution in ACB’s common shareholders.

Despite the dilution Charles Taerk, president and CEO of Faircourt Asset Management told the Investing News Network (INN) he sees Aurora’s shareholders as the second biggest winners of the entire transaction after LEAF holders.

“I think that shareholders of MedReleaf are saying ‘well why, if we are profitable and we are doing all these wonderful things, why don’t we have that higher valuation, that higher market cap and the multiple on or the basis upon which we are being valued?’” Taerk said.

“To join Aurora, [MedReleaf shareholders] are getting a premium and if they do hold on to the stock going forward, Aurora seems to have good attention in the market and are getting a premium valuation, so it will be a good lift for MedReleaf shareholders.”

Taerk told INN even though Faircourt has not been an Aurora investor “over the last couple of months” he commends the company for finding companies that are undervalued and bringing them into the fold.

“They want to be the preeminent cannabis company and in order to do that you need to be aggressive when others aren’t,” he said.

But does this acquisition finally put Aurora ahead of their biggest competitors and the leaders of the cannabis market, Canopy Growth (TSX:WEED), in Taerk’s eyes?

“Well that’s still to be determined … I think that Canopy has less execution risk than Aurora,” he said. “Aurora is still chasing them but they want to be one-and-one with Canopy.”

Investor takeaway

Both MedReleaf and Aurora hold favorable projections on analyst research site aggregator TipRanks.

A recent report done by Echelon Wealth Partners analyst Russell Stanley said MedReleaf has an incredible upside to its market performance. While GMP Securities analyst Martin Landry maintained his “Hold” rating on Aurora last week and lowered his price target from C$11.00 to C$7.50 for one-year due to concerns with the new facilities Aurora had announced.

The announcement provided an early boost to both company’s stock performance. After the markets closed on Monday, that early boost had gone down. MedReleaf closed the day with a 1.45 percent increase in its share value, reaching a C$25.26 price per stock. Aurora, on the other hand, decreased in value 2.11 percent and finished the trading day with a closing price of C$7.90.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Editor’s Note: This story was updated to reflect percentage and price changes for MedReleaf and Aurora after the markets closed on Monday.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less